MXPA02009777A - Uso de galantamina para el tratamiento de la conducta neurosiquiatrica asociada con el padecimiento de alzheimer. - Google Patents
Uso de galantamina para el tratamiento de la conducta neurosiquiatrica asociada con el padecimiento de alzheimer.Info
- Publication number
- MXPA02009777A MXPA02009777A MXPA02009777A MXPA02009777A MXPA02009777A MX PA02009777 A MXPA02009777 A MX PA02009777A MX PA02009777 A MXPA02009777 A MX PA02009777A MX PA02009777 A MXPA02009777 A MX PA02009777A MX PA02009777 A MXPA02009777 A MX PA02009777A
- Authority
- MX
- Mexico
- Prior art keywords
- dose
- day
- galantamine
- treatment
- weeks
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19425900P | 2000-04-03 | 2000-04-03 | |
| PCT/EP2001/003553 WO2001074339A2 (en) | 2000-04-03 | 2001-03-28 | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02009777A true MXPA02009777A (es) | 2003-03-27 |
Family
ID=22716898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02009777A MXPA02009777A (es) | 2000-04-03 | 2001-03-28 | Uso de galantamina para el tratamiento de la conducta neurosiquiatrica asociada con el padecimiento de alzheimer. |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1272192A2 (sk) |
| JP (1) | JP2003528913A (sk) |
| KR (1) | KR20020086911A (sk) |
| CN (1) | CN1430514A (sk) |
| AU (2) | AU6584401A (sk) |
| BG (1) | BG107093A (sk) |
| BR (1) | BR0109770A (sk) |
| CA (1) | CA2310926C (sk) |
| CZ (1) | CZ20023543A3 (sk) |
| EE (1) | EE200200554A (sk) |
| HR (1) | HRP20020778A2 (sk) |
| HU (1) | HUP0300566A3 (sk) |
| IL (1) | IL152061A0 (sk) |
| MX (1) | MXPA02009777A (sk) |
| NO (1) | NO20024746L (sk) |
| PL (1) | PL361272A1 (sk) |
| RU (1) | RU2002129298A (sk) |
| SK (1) | SK15422002A3 (sk) |
| WO (1) | WO2001074339A2 (sk) |
| ZA (1) | ZA200207935B (sk) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6617361B2 (en) * | 1999-11-05 | 2003-09-09 | Be Able, Llc | Behavior chemotherapy |
| ATE374030T1 (de) | 2003-07-25 | 2007-10-15 | Hoffmann La Roche | Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten |
| DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
| WO2009120277A1 (en) | 2008-03-27 | 2009-10-01 | Chase Pharmaceuticals Corporation | Use and composition for treating dementia |
| WO2013160728A1 (en) | 2012-04-26 | 2013-10-31 | Alma Mater Studiorum - Universita' Di Bologna | Dual targeting compounds for the treatment of alzheimer's disease |
| BG66818B1 (bg) * | 2013-03-07 | 2019-01-31 | Berbee Beheer B. V. | Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки |
| CN107847504A (zh) * | 2015-05-18 | 2018-03-27 | 斯奈普泰克发展有限责任公司 | 淀粉状蛋白β的加兰他敏清除 |
| CN117957003A (zh) * | 2021-09-09 | 2024-04-30 | 上海日馨医药科技股份有限公司 | 治疗神经退行性疾病的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663318A (en) | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| DE19509663A1 (de) * | 1995-03-17 | 1996-09-19 | Lohmann Therapie Syst Lts | Verfahren zur Isolierung von Galanthamin |
| GB9600080D0 (en) * | 1996-01-04 | 1996-03-06 | Chiroscience Ltd | Resolution process |
| US7939522B1 (en) | 1998-11-23 | 2011-05-10 | Bonnie M Davis | Dosage formulations for acetylcholinesterase inhibitors |
| OA11740A (en) * | 1998-12-24 | 2005-05-13 | Janssen Pharmaceutica Nv | Controlled release galantamine composition. |
| CA2310950C (en) * | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
| CA2310990A1 (en) * | 2000-04-03 | 2000-10-09 | Michael Pontecorvo | A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease |
-
2000
- 2000-06-27 CA CA002310926A patent/CA2310926C/en not_active Expired - Lifetime
-
2001
- 2001-03-28 KR KR1020027011063A patent/KR20020086911A/ko not_active Application Discontinuation
- 2001-03-28 HU HU0300566A patent/HUP0300566A3/hu unknown
- 2001-03-28 EP EP01943200A patent/EP1272192A2/en not_active Withdrawn
- 2001-03-28 JP JP2001572084A patent/JP2003528913A/ja not_active Withdrawn
- 2001-03-28 CZ CZ20023543A patent/CZ20023543A3/cs unknown
- 2001-03-28 CN CN01807334A patent/CN1430514A/zh active Pending
- 2001-03-28 AU AU6584401A patent/AU6584401A/xx active Pending
- 2001-03-28 BR BR0109770-9A patent/BR0109770A/pt not_active IP Right Cessation
- 2001-03-28 RU RU2002129298/14A patent/RU2002129298A/ru not_active Application Discontinuation
- 2001-03-28 PL PL36127201A patent/PL361272A1/xx not_active Application Discontinuation
- 2001-03-28 WO PCT/EP2001/003553 patent/WO2001074339A2/en not_active Application Discontinuation
- 2001-03-28 EE EEP200200554A patent/EE200200554A/xx unknown
- 2001-03-28 SK SK1542-2002A patent/SK15422002A3/sk unknown
- 2001-03-28 AU AU2001265844A patent/AU2001265844B2/en not_active Ceased
- 2001-03-28 IL IL15206101A patent/IL152061A0/xx unknown
- 2001-03-28 MX MXPA02009777A patent/MXPA02009777A/es unknown
-
2002
- 2002-09-12 BG BG107093A patent/BG107093A/bg unknown
- 2002-09-26 HR HR20020778A patent/HRP20020778A2/xx not_active Application Discontinuation
- 2002-10-02 ZA ZA200207935A patent/ZA200207935B/en unknown
- 2002-10-02 NO NO20024746A patent/NO20024746L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2002129298A (ru) | 2004-03-27 |
| BR0109770A (pt) | 2003-02-04 |
| AU2001265844B2 (en) | 2005-04-14 |
| CA2310926A1 (en) | 2000-10-04 |
| ZA200207935B (en) | 2004-01-30 |
| JP2003528913A (ja) | 2003-09-30 |
| EE200200554A (et) | 2004-04-15 |
| CA2310926C (en) | 2002-10-15 |
| HUP0300566A2 (hu) | 2003-06-28 |
| CN1430514A (zh) | 2003-07-16 |
| PL361272A1 (en) | 2004-10-04 |
| CZ20023543A3 (cs) | 2003-03-12 |
| EP1272192A2 (en) | 2003-01-08 |
| SK15422002A3 (sk) | 2003-04-01 |
| WO2001074339A3 (en) | 2002-09-12 |
| NO20024746L (no) | 2002-11-28 |
| WO2001074339A2 (en) | 2001-10-11 |
| BG107093A (bg) | 2003-06-30 |
| NO20024746D0 (no) | 2002-10-02 |
| HUP0300566A3 (en) | 2004-10-28 |
| AU6584401A (en) | 2001-10-15 |
| KR20020086911A (ko) | 2002-11-20 |
| IL152061A0 (en) | 2003-05-29 |
| HRP20020778A2 (en) | 2004-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6334511B2 (ja) | 新規方法 | |
| Sival et al. | Sodium valproate in the treatment of aggressive behavior in patients with dementia—a randomized placebo controlled clinical trial | |
| Crow et al. | The coincidence of schizophrenia and Parkinsonism: some neurochemical implications | |
| CA2310950C (en) | An efficacious dosage regiment of galantamine that reduces side effects | |
| WO2021016369A1 (en) | Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder | |
| US20220184074A1 (en) | Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor | |
| MXPA02009777A (es) | Uso de galantamina para el tratamiento de la conducta neurosiquiatrica asociada con el padecimiento de alzheimer. | |
| JPH0667842B2 (ja) | 基本的うつ病を軽減するためのうつ病治療剤 | |
| AU2001265844A1 (en) | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease | |
| CN115427037A (zh) | 达立克生(daridorexant)的医药用途 | |
| Dominick et al. | Risperidone treatment for irritability in fragile X syndrome | |
| US12023315B2 (en) | Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis | |
| US20060172993A1 (en) | Use of galantamine for the treatment of neuropsychiatric behaviour associated with Alzheimer's disease | |
| Haimov | Melatonin rhythm abnormalities and sleep disorders in the elderly | |
| De Wilde et al. | A double‐blind randomized placebo‐controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression | |
| RU2818678C2 (ru) | Способы лечения хронической спонтанной крапивницы с применением ингибитора тирозинкиназы брутона | |
| JP2002517448A (ja) | 精神障害の治療用ｎｋ−１受容体アンタゴニストの使用 | |
| JP2007532624A (ja) | アルツハイマー病の治療のための療法組合せ | |
| US11752141B2 (en) | Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis | |
| WO2021055576A1 (en) | Combination of modafinil and an ampakine for improving cognition | |
| TW202333705A (zh) | 治療與阿茲海默症相關之激越的方法 | |
| JP2024540104A (ja) | アルツハイマー病に関連する激越を治療する方法 | |
| TW202302109A (zh) | 認知損傷之治療 | |
| Pitt et al. | A Review of the Use of Donepezil in the Treatment of Alzheimer’s Disease | |
| US20030130288A1 (en) | Method of treatment |